MCRB Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
593.0K
-19.4%
736.0K
+105.6%
358.0K
-18.3%
438.0K
+24.8%
351.0K
Cost of Revenue
0
0
0
0
0
Gross Profit
593.0K
-19.4%
736.0K
+105.6%
358.0K
-18.3%
438.0K
+24.8%
351.0K
Operating Expenses
16.7M
-23.9%
22.0M
+3.5%
21.3M
+7.3%
19.8M
-13.2%
22.8M
R&D
5.6M
-38.8%
9.1M
-30.7%
13.2M
+12.9%
11.7M
-7.4%
12.6M
SG&A
5.4M
-22.8%
7.1M
-12.5%
8.1M
+7.0%
7.5M
-20.4%
9.5M
Operating Income
-16152000
+24.1%
-21273000
-1.8%
-20907000
-7.9%
-19377000
+13.8%
-22477000
EBITDA
-9966000
+32.6%
-14796000
+26.5%
-20126000
-9.2%
-18423000
+14.0%
-21433000
Net Income
-16286000
-455.5%
4.6M
+123.0%
-19913000
-29.9%
-15335000
-286.9%
8.2M
EPS (Basic)
$-1.63
-446.8%
$0.47
+122.6%
$-2.08
-25.3%
$-1.66
-276.6%
$0.94
EPS (Diluted)
$-1.63
-446.8%
$0.47
+122.6%
$-2.08
-25.3%
$-1.66
-276.6%
$0.94
Shares (Diluted)
10.0M
+2.4%
9.7M
+1.7%
9.6M
+3.6%
9.2M
+5.4%
8.8M
Seres Therapeutics (MCRB) — Financials